12390 EL CAMINO REAL, SAN DIEGO, CA
Investor Presentation
Changes in Board, Management or Compensation
News, Reorganization Plan
To Acquire, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
RAISING 2025 FINANCIAL GUIDANCE RANGES AND REPORTING STRONG SECOND QUARTER 2025 RESULTS
Earnings Release
Shareholder votes
Q2
Q1
FY 2023
Q3
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party